Appointments: News From Sensei, DelMar, Seattle Genetics, Astellas, Galecto, Roivant Sciences And PDL BioPharma
This week's announcements include new CEOs at Sensei and DelMar, new chief medical officers at Seattle Genetics, Astellas Pharma, Galecto Biotech and Roivant Sciences, and new business development heads at Roivant and PDL BioPharma.
You may also be interested in...
Verona Pharma’s candidate COPD therapy ensifentrine has a first-in-class dual mechanism of action and is to be explored as an add-on to LAMA and LABA therapy in two Phase III clinical studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Bavencio’s Survival Benefit Confirmed In Front-Line Maintenance Therapy For Advanced Urothelial Cancer
Further details of Merck KGaA/Pfizer-funded JAVELIN Bladder 100 study presented at this year’s ASCO confirm avelumab’s survival benefit when used as front-line maintenance therapy in patients with advanced urothelial cancer that has not progressed following initial chemotherapy.